Questcor Pharmaceuticals, Inc. (
announced it would commence a phase II study to evaluate H.P.
Acthar for the treatment of patients with amyotrophic lateral
As per information provided by the ALS Association, patients
affected by ALS (also referred to as Lou Gehrig's disease) have
an average life expectancy of about 2-5 years from the time of
Around 40 patients will be enrolled in this 8-week,
randomized, open-label study designed to evaluate the safety and
tolerability of Acthar across four doses. Patients who
successfully complete the initial 8 weeks of trial will have the
option to participate in a 28-week open-label extension with a
3-week taper and 1-week follow-up period.
Acthar, an injectable drug, is the lead product at Questcor.
It is approved by the U.S. Food and Drug Administration for as
many as 19 indications such as nephrotic syndrome,
dermatomyositis, polymyositis, systemic lupus erythematosus,
rheumatoid arthritis, multiple sclerosis relapses and infantile
spasms. Questcor is also evaluating Acthar in other indications
such as diabetic nephropathy.
The company shipped 4,830 vials of Acthar during the first
quarter of 2013, up 17.5% year over year but down sequentially by
23.7%. In Apr 2013, Questcor shipped a record 2,550 vials of
Acthar to its distributor. In the first quarter, Acthar's
new paid prescriptions were about 1,725 - 1,750, up 16% year over
Questcor carries a Zacks Rank #3 (Hold). Right now,
Jazz Pharmaceuticals Public Limited Company (
looks well positioned with a Zacks Rank #1 (Strong Buy). Other
Avanir Pharmaceuticals, Inc. (
Lannett Company, Inc. (
are also attractive with a Zacks Rank #2 (Buy).
AVANIR PHARM (AVNR): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
QUESTCOR PHARMA (QCOR): Free Stock Analysis
To read this article on Zacks.com click here.